Latest News for: her2
Edit
Billings Gazette
13 Feb 2026
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for ...
Edit
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer
PR Newswire 13 Feb 2026
The trial is evaluating the company's developed IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate, HER2 ADC) as a first-line treatment for patients with unresectable locally advanced or metastatic HER2-positive breast cancer.
Edit
Kelun-Biotech Announces Fourth Indication for Sacituzumab Tirumotecan (sac-TMT) Approved by NMPA in HR+/HER2- Breast Cancer
PR Newswire 06 Feb 2026
Edit
Medical-imaging company Imagion Biosystems Lodges IND with FDA for Phase 2 Trial of MagSense� HER2 ...
Business Wire 04 Feb 2026
Edit
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced ...
Nasdaq Globe Newswire 03 Feb 2026
Edit
The Galveston Daily News
03 Feb 2026
Independent Multi-Vendor Study Validates BostonGene’s AI for Precision HER2 Scoring
Edit
The Galveston Daily News
03 Feb 2026
Medical-imaging company Imagion Biosystems Lodges IND with FDA for Phase 2 Trial of MagSense® HER2 ...
Edit
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer (Form 8-K) (Relay Therapeutics Inc)
Public Technologies 03 Feb 2026
for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer ... "Approximately 40% of patients with HR+/HER2- advanced breast cancer harbor PIK3CA ... About PIK3CA-mutated, HR+/HER2- Advanced Breast Cancer.
Edit
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer (Form 8-K) (ALX Oncology Holdings Inc)
Public Technologies 30 Jan 2026
Advanced HER2-Positive Breast Cancer. - Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer -.
Edit
ENHERTU® Approved in China as the First and Only HER2 Directed ADC for the Second-Line Treatment of Patients with HER2 Positive Metastatic Gastric Cancer (Daiichi Sankyo Co Ltd)
Public Technologies 22 Jan 2026
Press Release ENHERTU®Approved in China as the First and Only HER2 Directed ADC for the Second-Line Treatment of Patients with HER2 Positive Metastatic Gastric Cancer ... About HER2 Positive Gastric Cancer ... only) is a HER2 directed ADC.
Edit
Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
Nasdaq Globe Newswire 20 Jan 2026
Edit
Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Personalized Anthracycline Use in HR+/HER2- Early‑Stage ...
Business Wire 20 Jan 2026
Edit
HER2-Negative Metastatic Breast Cancer Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight ...
GetNews 17 Jan 2026
To Know in detail about the HER2-Negative Metastatic Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; ... Since HER2 is not overactive, HER2-targeted therapies like trastuzumab are ineffective.
Edit
The Galveston Daily News
12 Jan 2026
Bio-Sourcing and Zerion Pharma Join Forces to Develop First HER2 Oral Monoclonal Antibody Against Breast Cancer
- 1
- 2
- Next page »